Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
CJC-1295 and Ipamorelin, Explained
CJC-1295 and ipamorelin are unapproved growth-hormone-axis peptides. Here is what the evidence shows, and why we will not give you a starting dose.
CJC-1295 in sports medicine: the evidence
A 2026 UCLA scoping review found that CJC-1295's claimed benefits for musculoskeletal recovery and athletic performance remain unsubstantiated by human trials.
What is GEP44? A GLP-1/PYY explainer
GEP44 is an investigational peptide that pairs GLP-1 with peptide YY signalling to test whether weight loss can come with fewer GI side effects.
GLP-1 agonists and throat symptoms
A study of 617,000 patients found GLP-1 agonists are linked to cough, throat discomfort, and voice changes. Here is what the evidence shows and why.
GLP-1 drugs in longevity medicine: 2026
A 2026 review examines what AOMs like semaglutide and tirzepatide have demonstrated in longevity medicine, and where the evidence is still preliminary.
How chemists test what's in GLP-1 drugs
A new peer-reviewed method identifies nine GLP-1 drugs at once. Here is why that kind of identity testing matters right now.
GHK-Cu + BPC-157: reconstitution guide
How to reconstitute GHK-Cu and BPC-157, whether combining them in one vial is advisable, and how to calculate doses when concentrations differ.
LC-HRMS screens 9 GLP-1 agonists at once
A 2026 Hong Kong study validated a single LC-HRMS method covering nine GLP-1 receptor agonists, from approved drugs to investigational compounds.
Sports medicine peptides: the 2026 evidence
A 2026 UCLA scoping review found that the claimed benefits of BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu remain unsubstantiated by human trials.
Retatrutide and gallbladder disease risk
Retatrutide is an investigational GLP-1, GIP and glucagon triple agonist. Here is what the trial and label data show about gallbladder risk.
Obesity-driven HFpEF: the 2026 review
A 2026 systematic review maps how obesity drives HFpEF and frames SUMMIT trial data on tirzepatide into a practical clinical treatment approach.
Compounded tirzepatide with B6 explained
Compounded tirzepatide, including preparations with added vitamin B6, is not the licensed medicine. Here is what is documented and what is not.